BioTech StockTrader reports that a "twin" "triplet" alum* -- of Old Merck, and Schering-Plough -- Dr. Ismail Kola, now an EVP at UCB New Medicines, has this week joined the NASDAQ-traded clinical stage biopharma company's board of directors:
. . . .Dr. Kola currently serves as Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and also serves as President of UCB New Medicines, UCB’s discovery research through proof-of-concept organization, since November 2009. Prior to his current position, from March 2007 Dr. Kola served as Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, and Chief Scientific Officer at Schering-Plough Corporation. Previously, Dr. Kola held senior positions commencing in 2003 at Merck & Company, where he was Senior Vice President and Site Head, Basic Research, and responsible for atherosclerosis and cardiovascular diseases, diabetes, obesity, infectious diseases, immunology and rheumatology, animal pharmacology and basic and medicinal chemistry. Prior to that, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation. . . .
Dr. Kola currently serves on the board of directors of Astex Pharmaceuticals, Synosia andOndek. . . .
* Actually, he is not just a "twin" alum -- he is a "triplet" alum -- it looks like (per the end of the penultimate paragraph, in the blue pull-quote above) his stint at legacy Pharmacia must have overlapped with those of Fred Hassan and Carrie Cox. Wow. Small biopharm world.
No comments:
Post a Comment